- Previous Close
658.90 - Open
663.60 - Bid --
- Ask --
- Day's Range
638.60 - 668.95 - 52 Week Range
637.50 - 1,675.00 - Volume
276,097 - Avg. Volume
435,134 - Market Cap (intraday)
59.643B - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
33.44 - EPS (TTM)
19.35 - Earnings Date Jan 28, 2025 - Feb 1, 2025
- Forward Dividend & Yield 2.50 (0.39%)
- Ex-Dividend Date Sep 9, 2024
- 1y Target Est
1,381.33
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
www.strides.com3,065
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: STAR.NS
View MorePerformance Overview: STAR.NS
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STAR.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STAR.NS
View MoreValuation Measures
Market Cap
59.64B
Enterprise Value
79.38B
Trailing P/E
33.43
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.40
Price/Book (mrq)
2.63
Enterprise Value/Revenue
1.87
Enterprise Value/EBITDA
11.02
Financial Highlights
Profitability and Income Statement
Profit Margin
5.24%
Return on Assets (ttm)
6.78%
Return on Equity (ttm)
8.19%
Revenue (ttm)
44.1B
Net Income Avi to Common (ttm)
1.77B
Diluted EPS (ttm)
19.35
Balance Sheet and Cash Flow
Total Cash (mrq)
2.47B
Total Debt/Equity (mrq)
104.22%
Levered Free Cash Flow (ttm)
3.76B